Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis

ABSTRACT: The purpose of this post-trial access (PTA) program is to provide guselkumab to participants with Familial Adenomatous Polyposis (FAP) who are experiencing clinical benefit after completing 48 weeks of treatment in Study CNTO1959COR1001.

DISEASE(S): Adenomatous Polyposis Coli,Colorectal Neoplasms,Nasopharyngeal Neoplasms

PROVIDER: 2382264 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR